Shares of Intellia Therapeutics (NASDAQ:NTLA) were flat in pre-market trading after the company reported Q1 results.
Earnings per share were down 28.57% over the past year to ($0.63), which missed the estimate of ($0.44).
Revenue of $12,916,000 higher by 23.80% year over year, which missed the estimate of $18,140,000.
Earnings guidance hasn't been issued by the company for now.
Intellia Therapeutics hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: May 07, 2020
Time: 09:05 AM ET
Recent Stock Performance
52-week high: $19.00
52-week low: $9.18
Price action over last quarter: Up 7.12%
Intellia Therapeutics Inc is a genome editing company. It is engaged in developing curative therapeutics utilizing a biological tool known as CRISPR/Cas9. Its pipeline includes in vivo development programs targeting genetic diseases, including transthyretin amyloidosis and hereditary angioedema and ex vivo programs targeting Wilms Tumor 1 for acute myeloid leukemia.